Category Archives: Molecular Medicine

DUBLIN--(BUSINESS WIRE)--The "Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

The nuclear medicine global market is poised to grow at a high single digit CAGR from 2020 to 2027 to reach $10,742.7 million by 2027.

Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular levels for probing, tracking tissue function, study disease progression and assessing treatment responses.

Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.

The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at high teen CAGR from 2020 to 2027 due to technological advancements in the targeted treatment of cancers.

Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027 due to an increase in TC-99m isotope applications and product approvals.

Among SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Xenon (Xe-133), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for the largest share in 2020 and is projected to grow at a mid single digit CAGR from 2020 to 2027 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others.

Cardiology accounted for the largest share in 2020 and is expected to grow at mid single digit CAGR from 2020 to 2027 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2020 to 2027 due to increasing expanding usage in early screening tests in vulnerable populations in various developed countries.

PET is the fastest-growing segment with mid single digit CAGR from 2020 to 2027 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others.

Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027. Gallium (Ga-68) is expected to grow at high double digit CAGR from 2020 to 2027 due to an increase in usage as theranostic pair in assessing the suitability of patient for Lutathera and many emerging targeted radiotherapy agents.

PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for the largest share in 2020 and is projected to grow at high single digit CAGR from 2020 to 2027 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia related conditions.

Some of the key players of the nuclear medicine market are

Key Topics Covered:

1 Executive Summary

2 Introduction

3 Market Analysis

4 Nuclear Medicine Global Market, by Modality

5 Nuclear Medicine Global Market, by End-Users

6 Stable Isotopes

7 Nuclear Medicine Global Market by Region

8 Competitive Landscape

9 Major Player Profiles

For more information about this report visit https://www.researchandmarkets.com/r/so14du

Read this article:
Nuclear Medicine/Radiopharmaceuticals - Global Market Forecast to 2027: Production of Radiopharmaceuticals from Cyclotrons Gaining Momentum -...

Photo by Zo Meyers / inewsource

Above: The UC San Diego School of Medicine campus is shown on Feb. 1, 2020.

UC San Diego School of Medicine researchers announced Tuesday they have discovered a carbohydrate that the SARS-CoV-2 virus uses to latch onto a cellular molecule in the lungs, which has potential implications for treatment of COVID-19 patients.

Since January, researchers have known that the novel coronavirus primarily uses a molecule known as ACE2 which sits like a doorknob on the outer surfaces of the cells that line the lungs to enter and infect those cells. Finding a way to lock out that interaction between virus and doorknob as a means to treat the infection has become the goal of many research studies.

The UCSD researchers recently discovered the virus cannot grab onto that ACE2 doorknob without a carbohydrate heparan sulfate, which is also found on lung cell surfaces.

"ACE2 is only part of the story," said Jeffrey Esko, a professor of cellular and molecular medicine at UCSD and co-director of the Glycobiology Research and Training Center. "It isn't the whole picture."

Esko's study, published in the academic journal Cell, introduces a potential new approach for preventing and treating COVID-19.

His team demonstrated two approaches that can reduce the ability of the virus to infect human cells cultured in the lab by about 80 to 90%, either removing heparan sulfate with enzymes or using heparin as bait to lure and bind the coronavirus away from human cells.

Heparin, a form of heparan sulfate, is already a widely used medication to prevent and treat blood clots.

Esko's team has long studied heparan sulfate and the role it plays in health and disease.

The team discovered that the virus binds to heparin. When heparin is bound, the virus is able to bind to ACE2. The virus, the researchers found, must bind both heparan sulfate on the cell surface and ACE2 in order to get inside human lung cells grown in a laboratory dish.

With this viral entry mechanism established, the researchers next set about trying to disrupt it. They found that enzymes that remove heparan sulfate from cell surfaces prevent SARS-CoV-2 from gaining entry into cells. Likewise, treatment with heparin also blocked infection. The heparin treatment worked as an anti-viral at doses currently given to patients, even when the researchers removed the anticoagulant region of the protein the part responsible for preventing blood clots.

Esko cautioned that the findings are still far from translating into a COVID-19 treatment for people.

Researchers will need to test heparin and heparan sulfate inhibitors in animal models of SARS-CoV-2 infection. In a related study, UC San Diego scientists are also exploring the role human microbiomes, including the bacteria that live in and on the body, play in altering heparan sulfate and thus influencing a person's susceptibility to COVID-19.

"This is one of the most exciting periods of my career all of the things we've learned about heparan sulfate and the resources we've developed over the years have come together with a variety of experts across multiple institutions who were quick to collaborate and share ideas," Esko said.

KPBS' daily news podcast covering local politics, education, health, environment, the border and more. New episodes are ready weekday mornings so you can listen on your morning commute.

To view PDF documents, Download Acrobat Reader.

See the article here:
UCSD Researchers Discover Carbohydrate In Lungs That COVID-19 Uses To Infect - KPBS

A novel publication in the Nature journal Neuropsychopharmacology asserts that the stress of racism produces an increased risk for mental health disorders like anxiety and post-traumatic stress disorder in the Black community, especially in the current climate brought on by COVID-19 and the Black Lives Matter movement, leading to a critical need to utilize science to understand racisms true biological impact.

Wayne State University School of Medicine Professor of Psychiatry and Behavioral Neurosciences and the David and Patricia Barron Endowed Chair in PTSD and Trauma Neurobiology Tanja Jovanovic, Ph.D., wrote The critical importance in identifying the biological mechanisms underlying the effects of racism on mental health with Tracy Bale, Ph.D., a professor of Pharmacology at the University of Maryland School of Medicine in Baltimore.

Dr. Jovanovic has studied the impact of trauma on the brain and behavior in primarily African American urban communities for more than 15 years. The focus of her work has been in exposure to neighborhood and domestic violence, and post-traumatic stress disorder. She is now investigating the impact of racial discrimination above and beyond that of other types of trauma.

It is clear that the impact of racism is chronic, pervasive, and for many, unavoidable. Moreover it leaves the brain and body vulnerable to many disorders, including PTSD and many physical diseases, she said.

Her collaborator is a leading expert in understanding the impact of chronic stress on a molecular level. The duo decided to work together to examine the impact of the chronic stress of racism on biology. For a year, they studied biomarkers of stress that are also linked to immune system function.

Weve known for a long time that experiences of racial discrimination have a deep and long-term effect on psychology and mental health, and that there are substantial health disparities in that African American men and women are more likely to suffer from many medical illnesses compared to white individuals, Dr. Jovanovic said. A large part of this is due to systemic racism in health care, however, we believe racism also leaves an imprint on the body, which has not been well understood.

Dr. Bale works primarily with animal models of chronic stress and focuses on epigenetic and proteomic signatures of stress. Dr. Jovanovic focuses on African American women and children with urban trauma exposure who have experienced significant racism.

In writing this article, I contributed the information from individuals in Detroit reporting experiences of racism, especially in the current context of the Black Lives Matter movement, whileDr. Bale reported on the state-of-the art molecular methods that show the greatest promise as biomarkers of chronic stress and immune function, Dr. Jovanovic said.

She wants the field of stress and trauma research to focus on the impact of racism on the brain and the body. The duo are working on a series of grants and publications that describe these biological mechanisms in African American men and women in Detroit.

Black communities have been disproportionally affected by COVID-19; the pandemic has uncovered both systemic disparities and health-related vulnerability. It is truly of critical importance that we understand and mitigate the root causes of these vulnerabilities, she said.

Continue reading here:
New article shows how science could reveal racism's real impact on the body and brain - The South End

Cardiologist to the whos who of Houston for decades, Dr. James T. Willerson died at CHI St. Lukes Hospital Wednesday as the result of a long illness. He was 80. Most recently serving as president emeritus of the Texas Heart Institute, Willerson was recognized internationally for seminal research in stem cells for the repair of hearts and cardiovascular vessels injured by heart attacks.

Among those who counted Willerson as both a friend and personal cardiologist were former Secretarty of State James A. Baker, former Houston Mayor Bob Lanier, philanthropists Margaret Williams and Jeanie Kilroy, art dealer Meredith Long, famed restaurateur Tony Vallone and even famed heart surgeon Dr. Denton Cooley.

In fact, Willerson credited his meeting with Cooley when he was 14 years old, at a time when Cooley and his team had performed 10,000 heart operations, with leading him into cardiology. It was the beginning of a lifelong friendship and collaboration at the Texas Heart Institute.

So committed to his patients, Willerson was known to return phone calls to them back in Houston whether he was in China, Turkey or South America. His quiet nature and often abrupt manner in the exam room would belie his intense passion for serving his patients. He was at the very least once seen weeping at the funeral of one of his patients.

On the Texas Heart Institute Website, THI board chairman Eric Wade notes, Dr. Willerson lived a tremendous life defined by curiosity and an eternally burning flame for the study of the human heart and its myriad complexities, and on behalf of the Texas Heart Institute Board of Trustees, it is with a heavy heart that I share the news of his passing.

His bio at Texas Heart Institute tallies his numerous lauded positions and accolades: President of The University of Texas Health Science Center in Houston from 2001-2008, recently retired as the Edward Randall III Professor of Internal Medicine at The UT Medical School at Houston. He holds the Dunn Chair in Cardiology Research at THI, the Willerson/OQuinn Chair at THI, the James T. Willerson, MD Distinguished Chair in Cardiovascular Diseases at UT Southwestern Medical School in Dallas and The Institute of Molecular Medicine IMM at the University of U.T. Health Houston. He has been named a Distinguished Alumnus at the University of Texas, Austin, and at the Baylor College of Medicine. A swimming scholarship is named in his honor at The University of Texas at Austin.

Born in Lampasas to two physicians, Willerson graduated Phi Beta Kappa from the University of Texas where he led the swimming team to a state championship. But it was UT football that was his passion second only to medicine. He attended Baylor College of Medicine in Houston and completed his training in internal medicine and cardiology at Massachusetts General Hospital in Boston and Harvard Medical School.

Funeral arrangements are being handled by Geo. H. Lewis & Sons.

Read more from the original source:
Highly Revered Cardiologist Dr. James T. Willerson Passes Away at St. Luke's in Houston - PaperCity Magazine

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) turns six years old next month and over that time, its developed a reputation as one of the best-performing healthcare ETFs, biotechnology or otherwise.

That success is attributable to the ability of ARK Invests managers to identify disruptive genomics equities well before markets fully appreciate the growth stories behind those names.

Consider the investment opportunity found in the Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR, genome-editing platform. CRISPR is a genome-editing platform that will address the worlds most salient health issues. It is like a molecular swiss army knife with a rapidly expanding number of tools that perform different functions.

The major premise behind ARK Funds, and likely the reason for the success is the belief that the market at large does not know how to efficiently price and value the type of innovation these ETFs are investing in, according to Seeking Alpha. The returns of the individual funds are excellent, and they are excellent over extended periods of time.

The actively managed ARKG offers investors a thematic multi-capitalization exposure to innovative elements that cover advancements in gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations.

ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision; restructuring health care, agriculture, pharmaceuticals, and enhancing our quality of life.

Theres potentially epic growth to be had with ARKG because of where many of the funds components are in the clinical trial stages.

One of the biggest drivers for this placement, in my mind, is centered in the stages of clinical trials that most of the vaccine and therapeutics in the holdings are in, according to Seeking Alpha. They are mostly, if not all, pre-phase 1 through phase 3, placing them at least a year or two away from being in the market. This means they are some time away from generating significant earnings and bringing valuation metrics more in line with the broader market.

Genomics companies try to better understand how biological information is collected, processed and applied by reducing guesswork and enhancing precision; restructuring health care, agriculture, pharmaceuticals, and enhancing our quality of life.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

See the article here:
Why This Genomics ETF Is a Long-Term Winner - ETF Trends

The research led by Jeremy Wood, Zach Porterfield and Jamie Sturgill in the Department of Internal Medicine; Beth Garvy in Microbiology, Immunology & Molecular Genetics; and Wally Whiteheart in Molecular & Cellular Biochemistry, suggests localized inflammation in the lungs caused by COVID-19 may be responsible for the increased presence of blood clots in patients.

The study also provides evidence suggesting the risk of thrombosis could persist after the infection clears.

The study examined the blood of 30 COVID-19 patients including 15 who were inpatients in the intensive care unit, and 15 who received care as outpatients at UKs Infectious Diseases Clinic, along with eight disease-free volunteers who acted as a control group.

Compared to baseline, the COVID-19 patients had elevated levels of tissue factor, a protein found in blood that initiates the clotting process. Patients also had reduced levels of protein S, an anticoagulant that helps prevent blood clotting.

The researchers concluded that lung inflammation caused by COVID-19 is what leads to a decrease in protein S. Thisinflammation also causes immune and possible endothelial cell activation, which leads to increased tissue factor protein.

What weve learned is that the clotting is not caused by anything systemic. Localized inflammation in the lungs is whats driving this whole process, Wood said. With an increase in tissue factor and a deficiency in protein S, COVID-19 patients get more blood clotting without the ability to shut it down or control it.

The study additionally showed that protein S levels remained low in some patients even after they tested negative for COVID-19, which suggests that blood clotting issues may persist after infection and long-term monitoring of thrombotic risk may be necessary.

Wood says this preliminary data could be a cause for concern. Certain viruses like HIV are linked to a long-term deficiency in protein S, which causes an ongoing risk of thrombosis in patients. It is not yet known if COVID-19 could cause a similar persisting protein S deficiency.

Tissue factor and protein S are good markers to monitor for long-term thrombosis risk and the data suggest that we need to be monitoring these patients because were not seeing these parameters corrected immediately, Wood said.

The research team recently received a grant from UKsCenter for Clinical and Translational Science(CCTS) to begin a longitudinal study to look at these levels in patients over the next year.

This will help answer the question: will this risk remain like it is in the HIV patients or will it go away?

The study was funded in part by anAlliance Grantthrough the College of Medicine as well as UKsCOVID-19 Unified Research Experts (CURE) Alliancethroughthe Vice President for Research and the College of Medicine and the CCTS. It was a product of collaboration between a number of different groups at UK that have been studying COVID-19.

Additional collaborators includeMartha Sim, Meenakshi Banerjee and Hammodah Alfar in the Department of Molecular and Cellular Biochemistry; Melissa Hollifield and Jerry Woodward with Microbiology, Immunology and Molecular Genetics; Xian Li with the Saha Cardiovascular Research Center; Alice Thornton with the Division of Infectious Disease; and Gail Sievert, Marietta Barton-Baxter and Kenneth Campbell with CCTS.

Link:
UK research getting to bottom of COVID clots - ABC 36 News - WTVQ

FREMONT, Calif., Sept. 17, 2020 /PRNewswire/ -- The global precision medicine marketis projected to reach $278.61 billion by 2030, reveals a premium market intelligence report by BIS Research. The study also highlights that the market is set to witness a CAGR of 11.13% during the period between 2020 and 2030.

The comprehensive study of the global precision medicine market by BIS Research extensively covers the following:

The detailed report is a compilation of 19 Market Data Tables and 330 Figures spread through 529 Pages and in-depth TOC on "Global Precision Medicine Market"

Besides these parameters, the report also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 1400+ products.

The BIS Research report indicates that the increasing number of genetic tests taken, the growing demand for reliable next-generation sequencing (NGS) results, the rising prevalence of infectious diseases, and the improving funding scenario in the field of precision medicine, among others, are fueling the growth of the market.

It also highlights the various emerging opportunities, such as growth in emerging nations, capitalization on the high prevalence of cancer, and the evolution of technology in healthcare, that can be leveraged by players operating in the market.

Additionally, the market intelligence report by BIS Research throws a spotlight on the key industry trends that have a humungous influence in shaping the industry going forward. Some of these trends include the emergence of advanced stabilization products, regulated vs. multimodal analysis, collaborations and partnerships, and several other key trends.

View the Report from BIS Research: Global Precision Medicine Market

Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include types of products offered, technologies used, sources used, applications, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The technology and ecosystem analysis of the global market includes data analysis on the satisfaction level of different pricing analysis of preferred instruments, accessories and components, and consumables. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as consumables and instruments. The consumables are further categorized into kits and reagents.

Emphasizing the dominance of North America in global precision medicine market in 2019 and 2020, Nitish Kumar Singh, Lead Analyst BIS Research, states, "InNorth America, several established diagnostics manufacturers are focusing on expanding their portfolio in NGS-based molecular diagnostics and are collaborating with service providers and pharmaceutical giants to co-market molecular diagnostics solutions with its complementary precision medicine solutions. Moreover, the U.S. government is undertaking a number of initiatives to develop of precision drugs and tests for oncology and non-oncology diseases and provide funds to new startups in the molecular diagnostics and precision medicine field."

Request for a Sample: https://bisresearch.com/requestsample?id=964&type=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 40 leading companies, market participants, and vendors. The key players profiled in the report includeAbbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc., Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMrieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America, MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi SA, Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc.

The report also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

How can this market intelligence report on precision medicine add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies take Strategic Decisions

Related BIS Research Market Reports:

Global NGS Sample Preparation Market - Analysis and Forecast, 2019-2025

Global Next Generation Sequencing (NGS) Market - Analysis and Forecast, 2019-2024

Global Rare Disease Diagnostics Market - Analysis and Forecast, 2018-2025

About BIS Research:

BIS Researchis a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as, custom studies, and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 5 years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.

Contact:

Bhavya BangaEmail: [emailprotected] BIS Research Inc.39111 PASEO PADRE PKWY STE 313,FREMONT CA 94538-1686Visit our Blog @ https://blog.bisresearch.com/ Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-researchConnect with us on [emailprotected] https://twitter.com/BISResearch

SOURCE BIS Research

Link:
BIS Research Report Highlights the Global Precision Medicine Market to Reach $278.61 Billion by 2030 - PRNewswire

More than 1 million Americans are diagnosed with a chronic brain disorder each year, yet effective treatments for most complex brain disorders are inadequate or even nonexistent.

A major new research effort at the McGovern Institute for Brain Research at MIT aims to change how we treat brain disorders by developing innovative molecular tools that precisely target dysfunctional genetic, molecular, and circuit pathways.

The K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience was established at MIT through a $28 million gift from philanthropist Lisa Yang and MIT alumnus Hock Tan 75. Yang is a former investment banker who has devoted much of her time to advocacy for individuals with disabilities and autism spectrum disorders. Tan is president and CEO of Broadcom, a global technology infrastructure company.This latest gift brings Yang and Tans total philanthropy to MIT to more than $72 million.

In the best MIT spirit, Lisa and Hock have always focused their generosity on insights that lead to real impact," says MIT President L. Rafael Reif. Scientifically, we stand at a moment when the tools and insights to make progress against major brain disorders are finally within reach. By accelerating the development of promising treatments, the new center opens the door to a hopeful new future for all those who suffer from these disorders and those who love them. I am deeply grateful to Lisa and Hock for making MIT the home of this pivotal research.

Engineering with precision

Research at the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience will initially focus on three major lines of investigation: genetic engineering using CRISPR tools, delivery of genetic and molecular cargo across the blood-brain barrier, and the translation of basic research into the clinical setting. The center will serve as a hub for researchers with backgrounds ranging from biological engineering and genetics to computer science and medicine.

Developing the next generation of molecular therapeutics demands collaboration among researchers with diverse backgrounds, says Robert Desimone, McGovern Institute director and the Doris and Don Berkey Professor of Neuroscience at MIT. I am confident that the multidisciplinary expertise convened by this center will revolutionize how we improve our health and fight disease in the coming decade. Although our initial focus will be on the brain and its relationship to the body, many of the new therapies could have other health applications.

There are an estimated 19,000 to 22,000 genes in the human genome and a third of those genes are active in the brain the highest proportion of genes expressed in any part of the body. Variations in genetic code have been linked to many complex brain disorders, including depression and Parkinsons disease. Emerging genetic technologies, such as the CRISPR gene editing platform pioneered by McGovern Investigator Feng Zhang, hold great potential in both targeting and fixing these errant genes. But the safe and effective delivery of this genetic cargo to the brain remains a challenge.

Researchers within the new Yang-Tan Center will improve and fine-tune CRISPR gene therapies and develop innovative ways of delivering gene therapy cargo into the brain and other organs. In addition, the center will leverage newly developed single-cell analysis technologies that are revealing cellular targets for modulating brain functions with unprecedented precision, opening the door for noninvasive neuromodulation as well as the development of medicines. The center will also focus on developing novel engineering approaches to delivering small molecules and proteins from the bloodstream into the brain. Desimone will direct the center and some of the initial research initiatives will be led by associate professor of materials science and engineering Polina Anikeeva; Ed Boyden, the Y. Eva Tan Professor in Neurotechnology at MIT; Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Brain and Cognitive Sciences at MIT; and Feng Zhang, James and Patricia Poitras Professor of Neuroscience at MIT.

Building a research hub

My goal in creating this center is to cement the Cambridge and Boston region as the global epicenter of next-generation therapeutics research. The novel ideas I have seen undertaken at MITs McGovern Institute and Broad Institute of MIT and Harvard leave no doubt in my mind that major therapeutic breakthroughs for mental illness, neurodegenerative disease, autism, and epilepsy are just around the corner, says Yang.

Center funding will also be earmarked to create the Y. Eva Tan Fellows program, named for Tan and Yangs daughter Eva, which will support fellowships for young neuroscientists and engineers eager to design revolutionary treatments for human diseases.

We want to build a strong pipeline for tomorrows scientists and neuroengineers, explains Hock Tan. We depend on the next generation of bright young minds to help improve the lives of people suffering from chronic illnesses, and I can think of no better place to provide the very best education and training than MIT.

The molecular therapeutics center is the second research center established by Yang and Tan at MIT. In 2017, they launched the Hock E. Tan and K. Lisa Yang Center for Autism Research, and, two years later, they created a sister center at Harvard Medical School, with the unique strengths of each institution converging toward a shared goal: understanding the basic biology of autism and how genetic and environmental influences converge to give rise to the condition, then translating those insights into novel treatment approaches.

All tools developed at the molecular therapeutics center will be shared globally with academic and clinical researchers with the goal of bringing one or more novel molecular tools to human clinical trials by 2025.

We are hopeful that our centers, located in the heart of the Cambridge-Boston biotech ecosystem, will spur further innovation and fuel critical new insights to our understanding of health and disease, says Yang.

Read more:
New molecular therapeutics center established at MIT's McGovern Institute - MIT News

Without masks and a vaccine, we could reach Herd Immunity from COVID-19, but deaths would skyrocket. We break down the science of it. USA TODAY

Scientists and physicians reacted with words such as aghast, despicable and outrageous over the weekend as news spread that White House appointeesinterfered with a basic national public health reportwhen it conflicted with PresidentDonald Trump'scoronavirus messaging.

Michael Caputo, the Health and Human Services assistant secretary for public affairs, acknowledged Saturday that since June, he and an adviser havescrutinized and at times pushed for changes toa weekly health report distributed by the U.S. Centers for Disease Control and Prevention.

The meddling, first reported by Politico,included efforts to stop the publication of a report last week on the use of hydroxychloroquine,a malaria drug often touted by Trump, delaya10-state study of COVID-19 infection statistics in Juneand another on the spread of coronavirus at a Georgia sleep-away camp.

The Morbidity and Mortality Weekly Report is a series of dry and sometimes dense briefupdates on public health incidents that comeout on Thursdays. They typically describeevents or topicsand are an important way for doctors and health officials to get the latest data.

Monday, members of the House Select Subcommittee on the Coronavirus Crisis sent a letter to HHS Secretary AlexAzar and CDC Director Robert Redfield requesting documents pertaining to the efforts to block the publicationof "accurate scientific reports."

"We are gravely concerned by reports showing that the Presidents political appointees at HHS have sought to help him downplay the risks of the coronavirus crisis by attempting to alter, delay, and block critical scientific reports from CDC," the letter said.

Approving a vaccine in the U.S. usually takes years, but COVID-19 vaccines are moving through in record time. What does that mean? USA TODAY

The sprint to create a COVID-19 vaccine started in January. The finish line awaits.

Dr. William Schaffner, who is on the publications editorial board, said he was aghast and appalled" by the reported attempts to delay, stop or change reports.He described the publication as a vital part of the global conversation among public health officials who track diseases and dangers.

It has been the voice of the U.S. governments health system, of integrity and scientific rigor, for years," said Schaffner, a professor and infectious disease expert at the Vanderbilt University School of Medicine in Nashville, Tennessee."Indeed, the MMWR has been a model for other countries ministries of public health for creating similar newsletters in their countries.

The interference is not just anti-science butdisinformation intended to deceive the American public, said Dr. Eric Topol, a professor of molecular medicine at the Scripps Research Institute in La Jolla, California.

This is outright egregious. Its despicable, Topol said, accusing Redfieldand otherleadersof allowing the agency to be hijacked by politics.

Coronavirus in America: Here's how the virus is spreading, state by state

What were seeing is multiple actors, important people who are just laying down, who are complicit with the anti-science machinations of the Trump administration, he said.

In an interview Saturday with The Washington Post,Caputo alleged the content of the MMRWis being politicized by the agency itself.

But in an election year, and in the time of COVID-19,its no longer unanimously scientific. Theres political content, The Post quoted Caputo as saying.

On a Facebook livestream on Sunday night, Caputo railed against what he termed"sedition" among CDC scientists, the New York Times reported Monday.They havent gotten out of their sweatpants except for meetings at coffee shops to plot how theyre going to attack Donald Trump next, the Times reported him as saying. The Facebook video has since been removed.

On Twitter,Dr. Sherri Bucher, a global health researcher, wrote,There are no words to articulate how horrific this is. Trust & credibility, shattered, overnight. MMWR has been, for a long time, one of the most reliable, steadfast, scientific resources; unquestioned veracity, impeccable reputation for quality of data/analysis. No longer.

It is not unusual for communicationpeople within the CDC to be involved in an MMWR report before publication, said Dr. Patrick Remington, a member of the journals editorial board and a former CDC staffer.

That involvement was previously restricted to officials within the agency who let political leaders know what was coming so they could be prepared with a communicationstrategy, said Remington, associate dean for public health at the School of Medicine and Public Health at theUniversity of Wisconsin-Madison.

What is unusual is the allegation that the political process is attempting to influence the scientific conclusions. And thats a concern, Remington said.

A member of the editorial board for 14 years, Remington said the body meets roughly once a year to help decide the publication's big-picture vision. Its most recent meeting was in February.

Coronavirus Watch: An American dies of COVID-19 every 2 minutes

The board is not involved in the publication's day-to-day operations, and members knew nothing about the accusations of interferenceuntil they read about them, he and others said.

Jeff Niederdeppe, another member of the MMWR editorial board and a professor of public health communicationat Cornell University, said political meddling could erode public faith and cause long-term damage to the publication.

The big issue here in my mind is the fundamental undermining of trust, he said, both in the CDC generallyand among the public health practitioners who rely on the MMWR to make policy decisions. If that very foundation is being politicized, its incredibly alarming.

Regaining trust is a challenge, he said, and should begin with an immediate response from the CDC, which has not commented on the allegations.

If the concerns are confirmed, Niederdeppe said, Id be interested in convening with the other members of the MMWR editorial board to figure out what we could do in this role.

The Notes from the Field section of the MMWR previews small investigations by state or local health departments that illustrate a specific problem.

Theyre like an alert mechanism, Schaffner said.

MMWRs have described American heat-related deaths by sex and age, top foods contributing to high-salt intake, an outbreak of tuberculosis among workers at food processing plants and drinking rates among pregnant women.

Dr. Jennifer Kates, senior vice president of the nonprofit Henry J. Kaiser Family Foundation, which focuseson health issues, described the MMWR as the go-to public health publication.

The MMWR predates the CDC, beginning as a publication of the U.S. Public Health Servicein 1878.

Kates said she was disturbed by what appears to be the insertion of politics into a well-respected scientific journal. In general, the politicization of COVID has been the enemy of public health, she said.

MMWR reports are written by CDC staff, as well as public health workers and physicians nationwide. The one- to two-page reports are known for their meticulous and careful editing, a process those who'vegone through it described as harrowing.

If youve ever been involved as a co-author of one of those reports, its painful how carefully every sentence is reviewed for scientific rigor, for precision,Schaffner said.

The Centers for Disease Control and Prevention issues the Morbidity and Mortality Weekly Report every Thursday.(Photo: Jessica McGowan, Getty Images)

Read or Share this story: https://www.usatoday.com/story/news/health/2020/09/13/covid-scientists-white-house-meddling-cdc-mmwr/5787230002/

See the rest here:
Scientists outraged by White House appointees' meddling with coronavirus information: 'Outright egregious' - USA TODAY

HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] surged by $0.0 during the normal trading session on Thursday and reaching a high of $0.35 during the day while it closed the day at $0.34. The company report on September 8, 2020 that HTG Molecular Diagnostics to Present Corporate Overview at Fall Investor Conferences.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference. Details are as follows:.

About HTG.

HTG Molecular Diagnostics Inc. stock has also gained 6.01% of its value over the past 7 days. However, HTGM stock has declined by -52.85% in the 3 months of the year. Over the past six months meanwhile, it has lost -1.16% and lost -51.28% year-on date.

The market cap for HTGM stock reached $25.48 million, with 65.76 million shares outstanding and 49.64 million shares in the current float. Compared to the average trading volume of 4.77M shares, HTGM reached a trading volume of 2065978 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.

The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 0.04, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 1.77. The Price to Book ratio for the last quarter was 1.22, with the Price to Cash per share for the same quarter was set at 0.44.

HTG Molecular Diagnostics Inc. [HTGM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.01. With this latest performance, HTGM shares dropped by -27.00% in over the last four-week period, additionally sinking by -1.16% over the last 6 months not to mention a drop of -56.99% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 37.10, with the RSI for the last a single of trading hit 41.28, and the three-weeks RSI is set at 37.50 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 0.5115, while it was recorded at 0.3292 for the last single week of trading, and 0.5346 for the last 200 days.

Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -102.09 and a Gross Margin at +53.60. HTG Molecular Diagnostics Inc.s Net Margin is presently recorded at -100.49.

Return on Total Capital for HTGM is now -49.79, given the latest momentum, and Return on Invested Capital for the company is -53.22. Return on Equity for this stock declined to -85.65, with Return on Assets sitting at -43.42. When it comes to the capital structure of this company, HTG Molecular Diagnostics Inc. [HTGM] has a Total Debt to Total Equity ratio set at 71.00. Additionally, HTGM Total Debt to Total Capital is recorded at 41.52, with Total Debt to Total Assets ending up at 37.72. Long-Term Debt to Equity for the company is recorded at 50.39, with the Long-Term Debt to Total Capital now at 29.47.

Reflecting on the efficiency of the workforce at the company, HTG Molecular Diagnostics Inc. [HTGM] managed to generate an average of -$172,301 per employee. Receivables Turnover for the company is 4.70 with a Total Asset Turnover recorded at a value of 0.43.HTG Molecular Diagnostics Inc.s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.40.

With the latest financial reports released by the company, HTG Molecular Diagnostics Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HTGM.

There are presently around $6 million, or 34.30% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 5,060,160, which is approximately 0% of the companys market cap and around 0.80% of the total institutional ownership; COWEN PRIME SERVICES LLC, holding 4,579,500 shares of the stock with an approximate value of $1.57 million in HTGM stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $0.83 million in HTGM stock with ownership of nearly -3.68% of the companys market capitalization.

Positions in HTG Molecular Diagnostics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 17 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 1,592,904 shares. Additionally, 17 investors decreased positions by around 3,162,056 shares, while 8 investors held positions by with 11,662,409 shares. The mentioned changes placed institutional holdings at 16,417,369 shares, according to the latest SEC report filing. HTGM stock had 7 new institutional investments in for a total of 1,062,389 shares, while 11 institutional investors sold positions of 2,750,997 shares during the same period.

More:
HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? - The DBT News